Compositions and methods for reducing the risk of agent-induced liver toxicity
The present disclosure relates generally to a pharmaceutical compositions and methods of reducing acetaminophen-induced liver toxicity. The disclosure includes pharmaceutical compositions including acetaminophen and one or more components selected from S-adenosylhomocysteine (SAH), S-methylmethionine (SMM), or a pharmaceutically acceptable salt thereof. The disclosure also relates to methods of reducing acetaminophen-induced liver toxicity in a subject by administering or co-administering one or more of S-adenosylhomocysteine (SAH), S-methylmethionine (SMM), or a pharmaceutically acceptable salt thereof, with acetaminophen to a subject.
1. A pharmaceutical composition comprising: an effective amount of acetaminophen and an effective amount of one or more components chosen from S-adenosylhomocysteine (SAH), S-methylmethionine (SMM), or a pharmaceutically acceptable salt thereof.
2. The composition of claim 1 , wherein the component is S-adenosylhomocysteine (SAH).
3. The composition of claim 1 , wherein the component is S-methylmethionine (SMM).
4. The composition of claim 1 , wherein the composition consists essentially of: an effective amount of acetaminophen and an effective amount of one or more components chosen from S-adenosylhomocysteine (SAH), S-methylmethionine (SMM), or a pharmaceutically acceptable salt thereof.
5. The composition of claim 4 , wherein the component is S-adenosylhomocysteine (SAH).
6. The composition of claim 4 , wherein the component is S-methylmethionine (SMM).
7. The composition of claim 1 , wherein the composition consists of: an effective amount of acetaminophen and an effective amount of one or more components chosen from S-adenosylhomocysteine (SAH), S-methylmethionine (SMM), or a pharmaceutically acceptable salt thereof.
8. A method of reducing acetaminophen-induced liver toxicity in a subject comprising administering or co-administering an effective amount of one or more components chosen from S-adenosylhomocysteine (SAH), S-methylmethionine (SMM), or a pharmaceutically acceptable salt thereof, with an effective amount of acetaminophen to a subject.
9. The method of claim 8 , wherein the component is S-adenosylhomocysteine (SAH).
10. The method of claim 8 , wherein the component is S-methylmethionine (SMM).
11. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a composition comprising: acetaminophen and one or more components chosen from S-adenosylhomocysteine (SAH), S-methylmethionine (SMM), or a pharmaceutically acceptable salt thereof.